MIRA Pharmaceuticals, Inc.
MIRA
$1.42
-$0.01-0.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.13M | 5.20M | 4.71M | 5.81M | 6.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.87M | 8.06M | 8.02M | 8.64M | 9.72M |
| Operating Income | -7.87M | -8.06M | -8.02M | -8.64M | -9.72M |
| Income Before Tax | -7.77M | -7.92M | -7.85M | -11.24M | -12.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.77 | -7.92 | -7.85 | -11.24 | -12.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.77M | -7.92M | -7.85M | -11.24M | -12.78M |
| EBIT | -7.87M | -8.06M | -8.02M | -8.64M | -9.72M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.48 | -0.50 | -0.51 | -0.76 | -0.89 |
| Normalized Basic EPS | -0.30 | -0.31 | -0.32 | -0.47 | -0.55 |
| EPS Diluted | -0.48 | -0.50 | -0.51 | -0.76 | -0.89 |
| Normalized Diluted EPS | -0.30 | -0.31 | -0.32 | -0.47 | -0.55 |
| Average Basic Shares Outstanding | 65.26M | 63.06M | 61.19M | 59.41M | 57.98M |
| Average Diluted Shares Outstanding | 65.26M | 63.06M | 61.19M | 59.41M | 57.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |